前列泰胶囊联合左氧氟沙星治疗湿热挟瘀型慢性前列腺炎的临床观察及其对PSA、MIP-2、VCAM-1水平的影响  

Clinical observation of Qianlietai Capsules combined with levofloxacin in treatment of chronic prostatitis of damp-heat and blood stasis type and its effects on PSA, MIP-2, VCAM-1 levels

作　　者：王磊 洪正东[2] WANG Lei;HONG Zhengdong(Jiangxi Health Vocational College,Nanchang 330052,China;Department of Urinary Surgery,The Second Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]江西卫生职业学院,江西南昌330052 [2]南昌大学第二附属医院泌尿外科,江西南昌330006

出　　处：《药物评价研究》2021年第9期1939-1944,共6页Drug Evaluation Research

基　　金：江西省教育厅科学技术研究项目(GJJ161452);江西省教育厅科学技术研究项目(GJJ191408)。

摘　　要：目的探讨前列泰胶囊联合左氧氟沙星治疗湿热挟瘀型慢性前列腺炎的临床疗效及其对前列腺特异性抗原(PSA)、巨噬细胞炎性蛋白-2(MIP-2)、血管细胞黏附分子-1(VCAM-1)水平的影响。方法选取2019年1月—2020年6月于南昌大学第二附属医院就诊的湿热挟瘀型慢性前列腺炎患者84例作为研究对象,根据治疗方法将患者分为对照组(42例)与观察组(42例)。对照组患者口服左氧氟沙星片,0.2 g/次,3次/d。观察组患者在对照组的基础上口服前列泰胶囊,5粒/次,3次/d。两组均持续治疗6周。观察两组患者的临床疗效,比较两组治疗前后的美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、血清前列腺特异性抗原(PSA)、巨噬细胞炎性蛋白-2(MIP-2)和血管细胞黏附分子-1(VCAM-1)水平与尿动力学指标。结果治疗后,观察组总有效率为95.24%,显著高于对照组的78.57%(P<0.05)。治疗后,两组疼痛与不适、排尿症状、生活质量评分均低于治疗前(P<0.05);治疗后,观察组疼痛与不适、排尿症状、生活质量评分均显著低于对照组(P<0.05)。治疗后,两组血清PSA、MIP-2、VCAM-1水平均低于治疗前(P<0.05);治疗后,观察组血清PSA、MIP-2、VCAM-1水平均显著低于对照组(P<0.05)。治疗后,两组最大尿流率(MFR)、平均尿流率(AFR)和排尿量均大于治疗前(P<0.05);治疗后,观察组MFR、AFR、排尿量均大于对照组(P<0.05)。结论前列泰胶囊联合左氧氟沙星治疗湿热挟瘀型慢性前列腺炎疗效肯定,能减轻临床症状,改善尿动力学指标,调节血清PSA、MIP-2、VCAM-1水平,且未增加不良反应发生。Objective To investigate the clinical efficacy of Qianlietai Capsules combined with levofloxacin in treatment of chronic prostatitis of damp-heat and blood stasis type and its effects on prostate specific antigen(PSA), macrophage inflammatory protein-2(MIP-2), vascular cell adhesion molecule-1(VCAM-1) levels. Methods A total of 84 cases of chronic prostatitis with dampnessheat and stasis in the Second Affiliated Hospital of Nanchang University from January 2019 to June 2020 were selected as the research objects. According to the treatment methods, the patients were divided into control group(42 cases) and observation group(42 cases). Patients in the control group were po administered with Levofloxacin Tablets, 0.2 g/time, three times daily. Patients in the observation group were po administered with Qianlietai Capsules on the basis of control group, 5 capsules/time, 3 times daily. Both groups were treated for 6 weeks. The clinical efficacy of the two groups was observed, and the levels of NIH chronic prostatitis index(NIH-CPSI), serum prostate-specific antigen(PSA), macrophages inflammatory protein-2(MIP-2), and vascular cell adhesion molecular-1(VCAM-1) and urodynamic indexes were compared between two groups before and after treatment. Results After treatment, the total effective rate of observation group was 95.24%, which was significantly higher than 78.57% of control group(P < 0.05). After treatment, pain and discomfort, urination symptoms, and quality of life scores in two groups were lower than before treatment(P < 0.05). After treatment, the pain and discomfort, urination symptoms, and quality of life score of observation group were significantly lower than those of control group(P < 0.05). After treatment, the levels of serum PSA, MIP-2, and VCAM-1 in two groups were lower than before treatment(P < 0.05). After treatment, the levels of serum PSA, MIP-2, and VCAM-1 in observation group were significantly lower than those in control group(P < 0.05). After treatment, MFR, AFR and urine volume in two groups w

关 键 词：前列泰胶囊 左氧氟沙星 湿热挟瘀型 慢性前列腺炎 前列腺特异性抗原 巨噬细胞炎性蛋白-2 血管细胞黏附分子-1 

分 类 号：R983[医药卫生—药品]